NASDAQ · Biotechnology

Replimune Group, Inc. (REPL) Stock

$11.46 -4.42% NASDAQ: REPL Healthcare

Valuation

MetricValue
Price$11.46
Market Cap$1.08B
P/E Ratio-4.15
P/B Ratio11.98
P/S Ratio0.00
EPS (TTM)$-3.07
52-Week High$16.33
52-Week Low$1.50
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-159.32%
ROA-117.65%
ROCE-139.11%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity1.06
Current Ratio8.00

Annual Financials (USD)

Metric20222023202420252026
Revenue$0$0$0$0$0
Operating Profit$-121.0M$-177.0M$-235.0M$-262.0M$-320.0M
Net Profit$-118.0M$-174.0M$-216.0M$-247.0M$-314.0M
EPS$-2.26$-2.99$-3.24$-3.07$-3.38
Op Margin—————

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$461.0M$647.0M$488.0M$551.0M$332.0M
Total Liabilities$50.0M$91.0M$113.0M$135.0M$166.0M
Cash$106.0M$147.0M$74.0M$111.0M$209.0M
Borrowings$33.0M$61.0M$76.0M$76.0M$112.0M

Latest News

BMO Capital Upgrades Replimune to Outperform From Underperform, Adjusts PT to $16 From $1 MT Newswires · Jun 30, 2026 Wedbush Lifts Price Target on Replimune to $9 From $6, Maintains Neutral Rating MT Newswires · Jun 29, 2026 Replimune's Fiscal Q4 Net Loss Narrows MT Newswires · Jun 29, 2026 Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update GlobeNewswire · Jun 29, 2026 JPMorgan Upgrades Replimune Group to Overweight From Neutral, $17 Price Target MT Newswires · Jun 26, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$-82.0M$-128.0M$-185.0M$-192.0M$-280.0M
Investing Cash Flow$-4.0M$-145.0M$92.0M$-30.0M$307.0M
Financing Cash Flow$0$96.0M$0$97.0M$0
Net Cash Flow$-77.0M$41.0M$-72.0M$37.0M$98.0M
Free Cash Flow$-85.0M$-130.0M$-191.0M$-199.0M$-285.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.69
EV / EBITDA-3.52
FCF Yield-25.55%
Quick Ratio5.23
Interest Coverage-31.46
Return 1Y213.64%
Return 3Y-50.64%
Return 5Y-69.32%

Ownership

Insiders Held2.56%
Institutions Held95.37%
Institutions Float Held97.87%
Institutional HolderSharesReport Date
Baker Bros. Advisors, LP11,045,3362026-03-31
Price (T.Rowe) Associates Inc8,121,4332026-03-31
RTW Investments LP7,356,9162026-03-31
Blackrock Inc.6,239,2392026-03-31
Suvretta Capital Management, LLC4,221,8362026-03-31

About Replimune Group, Inc.

Replimune Group, Inc. is led by CEO Sushil Patel, employs 479 people, headquartered in US, publicly traded since 2018.

Replimune Group, Inc. (REPL) stock trades at $11.46 with a market capitalization of $1.08B. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.15, reflecting a net loss over the last twelve months, price-to-book of 11.98, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.50 and $16.33, and currently trades 29.8% below its 52-week high.

On profitability, Replimune Group, Inc. generates a return on equity (ROE) of -159.32% (negative, reflecting a net loss), return on capital employed of -139.11%.

Replimune Group, Inc. by the numbers, 2017–2026

Between 2017 and 2026 Replimune Group, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-314.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-297.0M.

Borrowings stand at $112.0M, cash from operations was $-280.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -73.2% over five years, and was -189.2% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Replimune Group, Inc. (REPL) — frequently asked questions

What is Replimune Group, Inc. (REPL) stock price today?

Replimune Group, Inc. (REPL) is currently trading at $11.46, down 4.42% today.

What is REPL P/E ratio?

Replimune Group, Inc.'s P/E ratio is -4.15. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is REPL return on equity (ROE)?

Replimune Group, Inc.'s return on equity (ROE) is -159.32%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Replimune Group, Inc.'s market cap?

Replimune Group, Inc. has a market capitalization of $1.08B.

Does REPL pay a dividend?

Replimune Group, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does REPL carry?

Replimune Group, Inc. has a debt-to-equity ratio of 1.06. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is REPL's profit margin?

Replimune Group, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is REPL in?

Replimune Group, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is REPL listed on?

Replimune Group, Inc. trades on NASDAQ under the ticker REPL.

What is REPL's 52-week range?

Over the last year Replimune Group, Inc. has traded between $1.50 and $16.33.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens REPL currently matches

On the figures above, Replimune Group, Inc. passes the filters for 4 of our ready-made screens, among them Small Cap Stocks, Stocks Under $100, Stocks Under $50. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Small Cap StocksStocks Under $100Stocks Under $50High Current Ratio Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.